TapewireFind a company

person · Reporting owner

Lacey David L.

Disclosed activity across 4 companies

Tapewire entity
38756
SEC CIK
0001734422

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Arcus Biosciences, Inc.RCUS · Entity 4104DirectorJune 11, 2026June 12, 2026
Atreca, Inc.BCEL · Entity 91940DirectorJune 13, 2023June 15, 2023
Nurix Therapeutics, Inc.NRIX · Entity 1156DirectorMay 15, 2026May 15, 2026
Unity Biotechnology, Inc.UBX · Entity 77428DirectorJune 18, 2020June 22, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcus Biosciences, Inc.

Report date June 11, 2026 · Filed June 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect76,652 Reported balance After 2026-06-11 transaction · row 1
1 source row

Row 1 · 2026-06-11 · Grant · Acquired 5,700 · Balance 76,652

F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2036-06-10Direct16,900 Reported balance After 2026-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-11 · Grant · Acquired 16,900 · Balance 16,900

F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Atreca, Inc.

Report date June 13, 2023 · Filed June 15, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2023-06-12Direct12,000 Reported balance After 2023-06-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-13 · Grant · Acquired 12,000 · Balance 12,000

F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.

Nurix Therapeutics, Inc.

Report date May 15, 2026 · Filed May 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14Direct31,250 Reported balance After 2026-05-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250

F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Unity Biotechnology, Inc.

Report date June 18, 2020 · Filed June 22, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.14 · Expires 2030-06-17Direct25,000 Reported balance After 2020-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-06-18 · Grant · Acquired 25,000 · Balance 25,000

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 18, 2020 or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 18, 2020 or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 11, 2026 Filed Jun 12, 2026 20:28 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (Right to Buy) · Derivative 16,900 $0.00 Strike: $23.30 $0.00
Disclosure

SEC source: 0001734422-26-000005 · wk-form4_1781296084.xml · derivative · entry 2

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,900

Underlying: Stock Option (Rights to Buy) · 16,900 shares

Expires 2036-06-10

F2 · derivative.exercise_date: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Read SEC document
June 11, 2026 Filed Jun 12, 2026 20:28 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 5,700 $0.00 $0.00
Disclosure

SEC source: 0001734422-26-000005 · wk-form4_1781296084.xml · nonDerivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,652

F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

Read SEC document
May 15, 2026 Filed May 15, 2026 21:51 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantDirector Stock Option (right to buy) · Derivative 31,250 $0.00 Strike: $15.86 $0.00
Disclosure

SEC source: 0001734422-26-000002 · wk-form4_1778881888.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,250

Underlying: Common Stock · 31,250 shares

Expires 2036-05-14

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:28 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (Right to Buy) · Derivative 38,300 $0.00 Strike: $10.02 $0.00
Disclosure

SEC source: 0001724521-25-000088 · wk-form4_1749760091.xml · derivative · entry 2

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,300

Underlying: Common Stock · 38,300 shares

Expires 2035-06-09

F2 · derivative.exercise_date: The option will vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:28 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 13,300 $0.00 $0.00
Disclosure

SEC source: 0001724521-25-000088 · wk-form4_1749760091.xml · nonDerivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,952

F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

Read SEC document
May 19, 2025 Filed May 19, 2025 21:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantDirector Stock Option (right to buy) · Derivative 25,000 $0.00 Strike: $9.51 $0.00
Disclosure

SEC source: 0001549595-25-000079 · wk-form4_1747690372.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-05-18

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Read SEC document
January 23, 2025 Filed Jan 27, 2025 21:30 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 5,000 $0.00 Strike: $13.33 $0.00
Disclosure

SEC source: 0001724521-25-000015 · wk-form4_1738013395.xml · derivative · entry 2

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2035-01-22

F1 · derivative.exercise_date: The option is exercisable in 24 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company.

Read SEC document
June 06, 2024 Filed Jun 7, 2024 22:20 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (Right to Buy) · Derivative 24,000 $0.00 Strike: $15.90 $0.00
Disclosure

SEC source: 0001724521-24-000115 · wk-form4_1717798846.xml · derivative · entry 2

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2034-06-05

F2 · derivative.exercise_date: The option will vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Read SEC document
June 06, 2024 Filed Jun 7, 2024 22:20 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 8,400 $0.00 $0.00
Disclosure

SEC source: 0001724521-24-000115 · wk-form4_1717798846.xml · nonDerivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,652

F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

Read SEC document
May 20, 2024 Filed May 20, 2024 23:25 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantDirector Stock Option (right to buy) · Derivative 25,000 $0.00 Strike: $16.19 $0.00
Disclosure

SEC source: 0001549595-24-000066 · wk-form4_1716247526.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-05-19

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 20, 2025, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Read SEC document
June 15, 2023 Filed Jun 17, 2023 00:08 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (Right to Buy) · Derivative 19,500 $0.00 Strike: $19.60 $0.00
Disclosure

SEC source: 0001209191-23-038145 · doc4.xml · derivative · entry 2

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2033-06-14

F2 · derivative.exercise_date: The option will vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Read SEC document
June 15, 2023 Filed Jun 17, 2023 00:08 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 6,800 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-038145 · doc4.xml · nonDerivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,252

F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

Read SEC document
June 13, 2023 Filed Jun 15, 2023 18:07 UTC Atreca, Inc. BCEL · Entity 91940 GrantStock Option (right to buy) · Derivative 12,000 $0.00 Strike: $1.18 $0.00
Disclosure

SEC source: 0001209191-23-037518 · doc4.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Class A Common Stock · 12,000 shares

Expires 2023-06-12

F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.

Read SEC document
May 04, 2023 Filed May 4, 2023 23:57 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantDirector Stock Option (right to buy) · Derivative 25,000 $0.00 Strike: $9.44 $0.00
Disclosure

SEC source: 0001209191-23-027508 · doc4.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-05-03

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 4, 2024, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Read SEC document
June 14, 2022 Filed Jun 16, 2022 20:23 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (Right to Buy) · Derivative 16,800 $0.00 Strike: $20.62 $0.00
Disclosure

SEC source: 0001209191-22-037412 · doc4.xml · derivative · entry 2

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,800

Underlying: Common Stock · 16,800 shares

Expires 2032-06-13

F3 · derivative.exercise_date: The option will vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Read SEC document
June 14, 2022 Filed Jun 16, 2022 20:23 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 4,100 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-037412 · doc4.xml · nonDerivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,452

F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

F2 · balance_after: Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2022.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 18:45 UTC Atreca, Inc. BCEL · Entity 91940 GrantStock Option (right to buy) · Derivative 12,000 $0.00 Strike: $2.09 $0.00
Disclosure

SEC source: 0001209191-22-036105 · doc4.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Class A Common Stock · 12,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.

Read SEC document
May 05, 2022 Filed May 6, 2022 21:40 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantDirector Stock Option (right to buy) · Derivative 17,500 $0.00 Strike: $10.39 $0.00
Disclosure

SEC source: 0001209191-22-027666 · doc4.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-05-04

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 5, 2023, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Read SEC document
June 09, 2021 Filed Jun 11, 2021 16:33 UTC Atreca, Inc. BCEL · Entity 91940 GrantStock Option (right to buy) · Derivative 12,000 $0.00 Strike: $10.27 $0.00
Disclosure

SEC source: 0001209191-21-039845 · doc4.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Class A Common Stock · 12,000 shares

Expires 2031-06-08

F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.

Read SEC document
June 03, 2021 Filed Jun 7, 2021 20:38 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (Right to Buy) · Derivative 14,100 $0.00 Strike: $24.79 $0.00
Disclosure

SEC source: 0001209191-21-038623 · doc4.xml · derivative · entry 2

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,100

Underlying: Common Stock · 14,100 shares

Expires 2031-06-02

F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control.

Read SEC document
June 03, 2021 Filed Jun 7, 2021 20:38 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 3,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-038623 · doc4.xml · nonDerivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,352

F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

Read SEC document
May 06, 2021 Filed May 24, 2021 23:49 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantDirector Stock Option (right to buy) · Derivative 17,500 $0.00 Strike: $27.38 $0.00
Disclosure

SEC source: 0001209191-21-035539 · doc4.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2031-05-05

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Read SEC document
June 18, 2020 Filed Jun 22, 2020 17:27 UTC Unity Biotechnology, Inc. UBX · Entity 77428 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $9.14 $0.00
Disclosure

SEC source: 0000899243-20-017393 · doc4.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-06-17

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 18, 2020 or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.

Read SEC document
June 10, 2020 Filed Jun 15, 2020 17:07 UTC Atreca, Inc. BCEL · Entity 91940 GrantStock Option (right to buy) · Derivative 12,000 $0.00 Strike: $17.87 $0.00
Disclosure

SEC source: 0001209191-20-036664 · doc4.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Class A Common Stock · 12,000 shares

Expires 2030-06-09

F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.

Read SEC document
May 21, 2020 Filed May 26, 2020 20:20 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 50,000 $0.00 Strike: $36.34 $0.00
Disclosure

SEC source: 0001209191-20-032004 · doc4.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-05-20

F1 · derivative.exercise_date: The option is exercisable in 36 equal monthly installments after May 21, 2020, subject to the Reporting Person's continued service to the Company.

Read SEC document
June 20, 2019 Filed Jun 24, 2019 16:11 UTC Unity Biotechnology, Inc. UBX · Entity 77428 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $9.00 $0.00
Disclosure

SEC source: 0001567619-19-013866 · doc1.xml · derivative · entry 1

Lacey David L. · CIK 0001734422 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2029-06-19

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 20, 2019 or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Non-Employee Director until such vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.